BioCentury
ARTICLE | Clinical News

TPI 287: Phase I started

January 26, 2015 8:00 AM UTC

Cortice said the H. Lee Moffitt Cancer Center and Research Institute began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV TPI 287, starting at a 14 mg/m 2 dose, concurrently with f...